ProfileGDS5678 / 1417331_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 83% 80% 81% 80% 75% 77% 79% 81% 80% 81% 83% 81% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7808581
GSM967853U87-EV human glioblastoma xenograft - Control 26.1042483
GSM967854U87-EV human glioblastoma xenograft - Control 35.6397780
GSM967855U87-EV human glioblastoma xenograft - Control 45.9547981
GSM967856U87-EV human glioblastoma xenograft - Control 55.7014280
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8476575
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1028277
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4770479
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7485681
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.742380
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8214881
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.072583
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7500581
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9094582